Patients with B cell malignancies that have relapsed or are resistant to treatment are currently getting CAR T cell therapy as standard care. Additionally, there is great therapeutic promise for autoimmune disorders with the development of genetically engineered T cells that can decrease B cells and plasma cells. In clinical trials, patients with non-Hodgkin lymphoma whose cancer reappeared after initial chemotherapy performed better with CAR T-cell therapy than with standard care.